Niagen (nicotinamide riboside) / ChromaDex - LARVOL DELTA

The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. (PubMed, Nat Metab) - P=N/A | "To restore NAD+ levels, the main biosynthetic pathways have been targeted, with nicotinamide (Nam), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) being the most prominent boosters...Overall, these results indicate a dual effect of NR and NMN and their microbially produced metabolite NA: a sustained increase in systemic NAD+ levels and a potent modulator of gut health. ClinicalTrials.gov identifier: NCT05517122 ."

Journal

Runx2 acetylation enhances pulmonary inflammation in chronic obstructive pulmonary disease through activating CDK8. (PubMed, Respir Res) - "These results indicated that Sirt3 depletion-induced Runx2 acetylation contributes to CDK8 activation and pulmonary inflammation in the progression of COPD."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • Targeted Protein Degradation • RUNX2 • SIRT3

NAD+-mediated SIRT1-LKB1-AMPK signaling drives lipid remodeling and meat quality differences between Daweishan miniature and Arbor Acres chicken breeds. (PubMed, Front Vet Sci) - "The concentrations of NAD+ and its key precursors, including nicotinamide (NAM), nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR), were higher (p < 0.05) in the M1 as compared to the A1 chicken breed...These results indicate that M1 chickens exhibit enhanced metabolic regulation and protein-rich muscle with distinct lipid remodeling, whereas A1 broilers favor rapid growth and fat accumulation. The study provides mechanistic insight into breed-specific differences in muscle metabolism and meat quality, highlighting NAD+ and its signaling axis as key regulators of lipid homeostasis in chicken breast muscle."

Journal • Metabolic Disorders • STK11

Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training (clinicaltrials.gov) - P=N/A | N=16 | Not yet recruiting | Sponsor: ZHANG Jiaqi

New trial

SUNRISE: Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants (clinicaltrials.gov) - P2/3 | N=40 | Not yet recruiting | Sponsor: University of California, Davis | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial primary completion date

Nicotinamide Riboside Mitigates Antiphospholipid Antibody-Induced Dysfunction in Human Trophoblast Cells. (PubMed, Am J Reprod Immunol) - "NR mitigated some, but not all, aPL-induced trophoblast dysfunction. This provides new insight into the role of antioxidant therapies on aPL-induced pregnancy complications, and a possible new avenue of managing obstetric APS to explore further."

Journal • Genetic Disorders • Hematological Disorders • Inflammation • Obstetrics

SIRT2 Mitigates Radiation-Induced Oral Mucositis by Promoting Homologous Recombination-Mediated DNA Double-Strand Break Repair in Epithelial Stem Cells. (PubMed, Cancer Lett) - "Importantly, SIRT2 activation-achieved via NAD+ supplementation in vitro or nicotinamide riboside (NR) in vivo-does not compromise the tumoricidal efficacy of IR in HNSCC models. These findings uncover a previously unrecognized protective role for SIRT2 in mucosal radiation injury and establish its activation as a promising, non-oncogenic therapeutic strategy to mitigate RIOM in patients receiving radiotherapy for head and neck cancer."

Journal • Head and Neck Cancer • Mucositis • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Stomatitis

Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential. (PubMed, Int J Mol Sci) - "By outlining overlapping and complementary mechanisms, we highlight NR and BBR as rational combinatorial strategies to restore mitochondrial resilience. This integrative perspective may guide the design of next-generation clinical trials and advance precision approaches in mitochondrial medicine."

Journal • Review • Cardiovascular • CNS Disorders • Metabolic Disorders • Ophthalmology

Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. (PubMed, J Peripher Nerv Syst) - "At present oral NR supplementation, at the doses used in this study, cannot be recommended to prevent neuropathy or to improve nerve regeneration."

Clinical • Journal • Pain

NiRiD: Nicotinamide Riboside for Diabetic Neuropathy (clinicaltrials.gov) - P1/2 | N=10 | Terminated | Sponsor: University of Maryland, Baltimore | N=54 ➔ 10 | Suspended ➔ Terminated; Completed the pilot study and grant funding not obtained to continue to the main phase 2 study. The pilot study did not show a statistical significance in the primary or secondary outcome measures.

Enrollment change • Trial termination • Diabetic Neuropathy • Pain

Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats. (PubMed, Hepatol Commun) - "NR promotes liver regeneration after PVE in obese rats by enhancing NAD+-dependent metabolic pathways through the MCART1/ASB3 axis, offering a potential therapeutic strategy for obesity-associated liver dysfunction."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Genetic Disorders • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Dimephosphon Radioprotective Properties on the Model of Radiation Injury In Vivo. (PubMed, Acta Naturae) - "It was shown that 14-day administration of the drug at a dose of 750 mg/kg after single-dose (5 Gy) irradiation of CD-1 mice resulted in a local radioprotective effect, reducing the severity of the radiation-induced injury to the intestinal epithelium and splenic capsule. The results of metabolomic screening revealed that the levels of the key metabolites responsible for antioxidant properties such as alpha-tocopherol, nicotinamide riboside, N-carbamoyl-L-aspartate, and adenylosuccinate were significantly increased, indicating that the Dimephosphon drug provides enhanced antioxidant protection."

Journal • Preclinical • Oncology

Developing Topics. (PubMed, Alzheimers Dement) - "NR is well-tolerated in older adults with MCI and may enhance perfusion of the hippocampus regardless of underlying AD pathology. However, this was not associated with improved memory performance in this short-duration trial. A larger phase-III trial over a longer treatment duration is warranted to determine the efficacy of NR for delaying cognitive impairment due to ADRD."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders

SERCA2 dysfunction stimulates inflammation and causes pulmonary vascular remodeling by downregulating PPARγ/PGC1α/Nrf2. (PubMed, Eur J Pharmacol) - "Targeting to improve PPARγ with pioglitazone, PGC1α with nicotinamide riboside, or to suppress reactive oxygen species (ROS) with 4-Hydroxy-TEMPO could efficiently ameliorate SERCA2 dysfunction-induced pulmonary vascular remodeling. Our study elucidates the direct regulation of SERCA2 dysfunction in initiating inflammation, which promotes cell proliferation, migration, and recruitment of inflammatory cells in PASMCs, ultimately contributing to the development of pulmonary vascular remodeling. Furthermore, SERCA2, PPARγ, PGC1α, and ROS may serve as potential therapeutic targets in the prevention and treatment of pulmonary hypertension."

Journal • Cardiovascular • Hypertension • Inflammation • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • PPARG

Nicotinamide riboside alleviates sepsis-induced acute kidney injury by suppressing ferroptosis. (PubMed, J Mol Med (Berl)) - "Sepsis-induced acute kidney injury (SAKI) is the predominant type of acute kidney injury encountered in intensive care units. Using EX527 or SIRT1 knockdown abolished NR-mediated ferroptosis alleviation. SIRT1 overexpression mimicked NR's protective function in inhibiting ferroptosis."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Critical care • Infectious Disease • Nephrology • Renal Disease • Septic Shock • ACSL4 • GPX4

Targeting PGC-1α axis Rescues Aberrant Development from Thyroid Hormone Defect in Brain Organoids. (PubMed, Pharmacol Res) - "Most importantly, pharmacological stimulation of the PGC-1α axis with Nicotinamide Riboside or Bezafibrate rescues mitochondrial bioenergetics and neuronal development, effectively correcting aberrant brain organoid maturation despite T3 deficiency. These findings reveal for the first time the role of T3 in supporting neurodevelopment via activation of mitochondrial β-oxidation and OXPHOS biogenesis, and identify the PGC-1α axis as a promising therapeutic avenue for otherwise intractable disorders linked to thyroid hormone deficiency."

Journal • Developmental Disorders • Mental Retardation • PPARGC1A

Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Eye & ENT Hospital of Fudan University

New trial

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation (ASH 2025) - P1 | "In the human umbilical cord blood setting, nicotinamide-based cell expansiontechnology (NiCord) has been used ex-vivo to expand the number of donor cells, while maintaining theirfunction. We conclude that NR supplementation is safe and well tolerated in alloBMT with dose dependentincreases in NAD+/NADPH levels that preliminarily are associated with more rapid PE and shorter LOS. These findings may have implications for improved resource utilization and cost-effectiveness in alloBMT,which will be further assessed as the trial proceeds to cohort 4."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Pneumonia • Respiratory Diseases • Transplantation • TINCR

Comparison of anti-aging effect of PQQ (Pyrroloquinoline Quinone) and NMN/NR (Nicotinamide Mononucleotide /Nicotinamide Riboside) - possible combination use. (PubMed, Ageing Res Rev) - "Despite supporting preliminary data and patented formulations, strong scientific evidence encouraging the synergistic anti-aging potential of PQQ and NMN/NR remains limited, highlighting the need for robust studies. Collectively, PQQ and NMN/NR offer distinct complementary strategies to promote healthy aging and prevent age-related diseases; their combination could offer a more effective approach to enhance healthy aging and longevity."

Journal • Review

Defective mitophagy of CD4+T cells in ITP via NAD+/SIRT1 reduction (ASH 2025) - "Nicotinamide riboside (NR) and a SIRT1 agonist (SRT1720) were administered to ITPCD4+ T cells in vitro to reveal the role of the NAD+/SIRT1 axis in mitophagy deficiency. GSEA revealed that the expression oftype I interferon in ITP CD4+ T cells and the pathways positively regulated by type 1 interferon weresignificantly upregulated, suggesting that mitophagy deficiency may promote the production of type Iinterferons by CD4+ T cells in ITP, thereby participating in the immune imbalance in ITP.ConclusionDefects in the NAD+/SIRT1 axis lead to mitophagy deficiency in ITP CD4+ T cells, resulting in an immuneimbalance in ITP. Targeted correction of the NAD+/SIRT1 axis can regulate CD4+ T-cell differentiationthrough the correction of mitophagy in ITP CD4+ T cells, providing new therapeutic ideas and targets forthe clinical treatment of ITP."

Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammation • Metabolic Disorders • Thrombocytopenia • Thrombocytopenic Purpura • BST1 • CD4 • PINK1 • SIRT1

Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. (PubMed, EClinicalMedicine) - P4 | "This work was supported by Niagen Bioscience, the MGH McCance Center for Brain Health, Lavine Brain Health Innovation Fund, MGH ECOR CDI Physician-Scientist Development Award, and the Alzheimer's Association (grant no. AARGD-23-114103)."

Clinical • Journal • CNS Disorders • Depression • Fatigue • Infectious Disease • Inflammation • Metabolic Disorders • Mood Disorders • Novel Coronavirus Disease • Psychiatry • Respiratory Diseases

Changes in hepatic phase Ⅱ detoxification enzymes and their mechanism in metabolic associated steatohepatitis (MASH) induced by MCD diet in mice (PubMed, Zhonghua Gan Zang Bing Za Zhi) - "The expression conditions of phase Ⅱ detoxification enzymes glutathione S-transferase mu 4 (GSTM4), dihydronicotinamide riboside:quinone oxidoreductases (NQO-2), sulfotransferase 1β1 (SULT1β1), and uridine diphosphate glucuronosyltransferase 2 family, polypeptide A3(UGT2A3) were verified by real-time fluorescent quantitative PCR...Western blotting showed that the expression of Nrf2, GSTM4, and UGT1A6 proteins was significantly lower in the MCD group than that in the NCD group (t=3.385, 2.990, 2.168, P<0.05). The expressions of multiple phase Ⅱ detoxification enzymes and antioxidant capacity are reduced in the liver of MASH mice induced by the MCD diet, and its mechanism is related to the down-regulation of the expression of the upstream regulatory factor Nrf2 protein."

Journal • Preclinical • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • CCL2 • IL1B • UGT1A6

Relationships of GDAP1 Mutations to Disease Phenotype and Mechanisms of Therapeutic Action of Oxidative Metabolism Activators in a Patient with Charcot-Marie-Tooth Neuropathy Type 2K. (PubMed, Biochemistry (Mosc)) - "Based on the found association of these substitutions with the axonal form of Charcot-Marie-Tooth disease (CMT) and disturbances in the NAD+- and thiamine diphosphate (ThDP)-dependent mitochondrial metabolism, the therapeutic effect of nicotinamide riboside (NR) and thiamine (precursors of NAD+ and ThDP, respectively) in the patient is studied...Our results demonstrate the therapeutic potential of thiamine and NR in correcting metabolic dysregulation in CMT caused by mutations in GDAP1, suggesting the underlying molecular mechanisms. Genetic diagnostics and biochemical characterization of mechanisms involved in the pathogenicity of mutations in clinically asymptomatic patients or patients at the early CMT stages may increase the efficacy of therapy, as it is easier to protect from the accumulating metabolic damage than to reverse it."

Journal • Genetic Disorders • Metabolic Disorders • Pain • GDAP1

Nicotinamide riboside enhances the efficacy of gemcitabine and suppresses PDAC premalignant lesions via SIRT3 activation. (PubMed, Biochem Pharmacol) - "Moreover, NR significantly potentiated gemcitabine efficacy both in vitro and in subcutaneous PDAC models, demonstrating synergistic enhancement of chemotherapy-induced tumor cell death. These findings establish NR as a promising SIRT3-targeting adjuvant that both enhances the efficacy of standard chemotherapy and delays carcinogenesis, thereby overcoming therapeutic resistance in established PDAC and potentially impeding its development."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • SIRT3

N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Haukeland University Hospital | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Jun 2025

Trial completion • Trial completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia